Page last updated: 2024-11-06
azocyclotin
Description
Azocyclotin is an organotin fungicide that was widely used in agriculture to control a variety of pests, including mites, aphids, and other insects. It is a white, crystalline solid that is soluble in organic solvents. Azocyclotin is synthesized by reacting cyclohexylisocyanate with tin tetrachloride in the presence of a catalyst. It acts by interfering with the nervous system of insects, leading to paralysis and death. Azocyclotin has been shown to have a number of adverse effects on the environment, including toxicity to aquatic organisms, birds, and mammals. It can also persist in the environment for long periods of time, leading to bioaccumulation in food chains. Due to its environmental impact, azocyclotin has been banned in many countries. However, it is still used in some parts of the world, and its potential effects on human health are still under investigation.'
azocyclotin: has inhibitory effects on X. laevis metamorphosis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
azocyclotin : A member of the class of triazoles that is 1,2,4-triazole substituted at position 1 by a tricyclohexylstannyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 91634 |
CHEBI ID | 2959 |
SCHEMBL ID | 73254 |
Synonyms (35)
Synonym |
AC-12492 |
azocyclotin |
41083-11-8 |
NCGC00166174-01 |
CHEBI:2959 , |
tricyclohexyl(1h-1,2,4-triazol-1-yl)tin |
tri(cyclohexyl)-1h-1,2,4-triazol-1-yltin |
1-(tricyclohexylstannyl)-1h-1,2,4-triazole |
peropal |
(1h-1,2,4-triazolyl)tricyclohexylstannane |
(1h-1,2,4-triazol-1-yl)tricyclohexylstannane |
stannane, (1h-1,2,4-triazol-1-yl)tricyclohexyl- |
hsdb 6559 |
tri(cyklohexyl)-1h-1,2,4-triazol-1-ylstannium [czech] |
bay bue 1452 |
azocyclotin [bsi:iso] |
brn 0621636 |
einecs 255-209-1 |
tricyclohexyl(1,2,4-triazol-1-yl)stannane |
v4yrq367ke , |
tri(cyklohexyl)-1h-1,2,4-triazol-1-ylstannium |
unii-v4yrq367ke |
1h-1,2,4-triazole, 1-(tricyclohexylstannyl)- |
AKOS015903255 |
azocyclotin [iso] |
azocyclotin [hsdb] |
SCHEMBL73254 |
DTXSID2058091 |
ONHBDDJJTDTLIR-UHFFFAOYSA-N |
clermait |
tricyclotin |
azocyclotin, pestanal(r), analytical standard |
Q410926 |
1,2-diaza-4-azanidacyclopenta-2,5-diene;tricyclohexylstannanylium |
1-(tricyclohexylstannyl)-1h-1,2,4-triazole, |
Research Excerpts
Bioavailability
Drug Classes (2)
Class | Description |
organotin acaricide | |
triazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (5)
Potency Measurements
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 32.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 32.49 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.59 (4.65) | Search Engine Demand Index | 41.22 (26.88) | Search Engine Supply Index | 2.32 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |